Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00930176 · ClinicalTrials.gov registry record · Phase 3
A Study Investigating Treatment Factor X in People With Factor X Deficiency
A Phase 3 study, sponsored by Bio Products Laboratory.
- Completed
- Registry status
- Phase 3
- Development phase
- 16
- Enrollment target
NCT00930176 is a Phase 3 study that has completed, run by Bio Products Laboratory. The registered enrollment target is 16 participants.
The verdict
NCT00930176, a Phase 3 study, has completed, sponsored by Bio Products Laboratory.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 16 participants
- Enrollment target
Study Summary
The main objective of the study is to assess the pharmacokinetics of FACTOR X after a single dose of 25IU/kg. The secondary objectives of the study are to assess efficacy and safety of FACTOR X in the treatment of bleeding episodes over at least 6 months.
Interventions
- BIOLOGICAL Human Coagulation FACTOR X
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2010-01 |
| Est. Completion | 2013-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00930176
The ClinicalTrials.gov registry entry for NCT00930176 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bio Products Laboratory, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Human Coagulation FACTOR X is the first listed.
NCT00930176 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00930176 about?
NCT00930176 is a clinical study titled "A Study Investigating Treatment Factor X in People With Factor X Deficiency". The main objective of the study is to assess the pharmacokinetics of FACTOR X after a single dose of 25IU/kg. The secondary objectives of the study are to assess efficacy and safety of FACTOR X in the treatment of bleeding episodes over at least 6 months.
What is the current status of trial NCT00930176?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 16 participants. The study started on 2010-01. Estimated completion is 2013-11.
What interventions are being tested in trial NCT00930176?
The interventions under investigation include: Human Coagulation FACTOR X (BIOLOGICAL).
Who is sponsoring clinical trial NCT00930176?
This trial is sponsored by Bio Products Laboratory, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.